A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a Malaria vaccine candidate

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Noe, Amy R ^a   Espinosa, Diego ^b   Li, Xiangming ^c   Coelho Dos Reis, Jordana G A ^c   Funakoshi, Ryota ^c   Giardina, Steve ^a   Jin, Hongfan ^d   Retallack, Diane M ^d   Haverstock, Ryan ^d   Allen, Jeffrey R ^d   Vedvick, Thomas S ^e   Fox, Christopher B ^e   Reed, Steven G ^e   Ayala, Ramses ^a   Roberts, Brian ^a   Winram, Scott B ^a   Sacci, John ^f   Tsuji, Moriya ^c   Zavala, Fidel ^b   Gutierrez, Gabriel M ^a  

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

^d Pfenex Inc   (United States)

^e INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; MALARIA VACCINE; RECOMBINANT CIRCUMSPOROZOITE PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; IMMUNOLOGICAL ADJUVANT; PROTOZOAL PROTEIN;

AMINO TERMINAL SEQUENCE; ANALYSIS OF VARIANCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG PURIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMODIUM FALCIPARUM; PROTEIN EXPRESSION; PSEUDOMONAS FLUORESCENS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPOROZOITE; T LYMPHOCYTE; ANIMAL; C57BL MOUSE; CHEMISTRY; DISEASE MODEL; GENETICS; HEPG2 CELL LINE; IMMUNOLOGY; MALARIA, FALCIPARUM; METABOLISM; PROCEDURES; TRANSGENIC ORGANISM; VACCINATION;

PLASMODIUM FALCIPARUM; PSEUDOMONAS FLUORESCENS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; HEP G2 CELLS; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; MICE; MICE, INBRED C57BL; ORGANISMS, GENETICALLY MODIFIED; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; PSEUDOMONAS FLUORESCENS; RECOMBINANT PROTEINS; VACCINATION;

EID: 84907573576     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107764     Document Type: Article

References (62)

1. WHO (2013) Malaria Fact Sheet. Available: http://www.who.int/mediacentre/factsheets/fs094/en/. Accessed 7 March 2014.
2. Greenwood BM, Bojang K, Whitty C.J., Targett G.A. (2005) Malaria. Lancet 365: 1487-1498.
3. Hoffman SL, Goh LM, Luke T.C., Schneider I., Le TP, et al. (2002) Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 185: 1155-1164.
4. Roestenberg M, McCall M, Hopman J., Wiersma J, Luty AJ, et al (2009) Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 361: 468-477.
5. Kumar KA, Sano G, Boscardin S., Nussenzweig RS, Nussenzweig MC, et al. (2006) The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites. Nature 444: 937-940.
6. Trieu A, Kayala MA, Burk C, Molina D.M., Freilich DA, et al. (2011) Sterile protective immunity to malaria is associated with a panel of novel P. falciparum antigens. Mol Cell Proteomics 10: M111 007948.
7. Rathore D, Sacci JB, de la Vega P, McCutchan TF (2002) Binding and invasion of liver cells by Plasmodium falciparum sporozoites. Essential involvement of the amino terminus of circumsporozoite protein. J Biol Chem 277: 7092-7098.
8. Calvo-Calle J.M., Hammer J, Sinigaglia F., Clavijo P, Moya-Castro ZR, et al. (1997) Binding of malaria T cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo: identification of a universal T cell epitope in the Plasmodium falciparum circumsporozoite protein. J Immunol 159: 1362-1373.
9. Doolan DL, Hoffman SL, Southwood S, Wentworth P.A., Sidney J., et al. (1997) Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles. Immunity 7: 97-112.
10. Coppi A, Pinzon-Ortiz C, Hutter C., Sinnis P. (2005) The Plasmodium circumsporozoite protein is proteolytically processed during cell invasion. J Exp Med 201: 27-33.
11. Ballou WR (2009) The development of the RTS, S malaria vaccine candidate: challenges and lessons. Parasite Immunol 31: 492-500.
12. Tam JP, Clavijo P, Lu Y.A., Nussenzweig V., Nussenzweig R, et al. (1990) Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria. J Exp Med 171: 299-306.
13. Yoshida N, Nussenzweig RS, Potocnjak P, Nussenzweig V., Aikawa M. (1980) Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite. Science 207: 71-73.
14. Zavala F, Tam JP, Barr P.J., Romero PJ, Ley V, et al. (1987) Synthetic peptide vaccine confers protection against murine malaria. J Exp Med 166: 1591-1596.
15. Breman JG, Alilio MS, Mills A. (2004) Conquering the intolerable burden of malaria: what's new, what's needed: a summary. Am J Trop Med Hyg 71: 1-15.
16. Clyde DF, Most H, McCarthy V.C., Vanderberg J.P. (1973) Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci 266: 169-177.
17. Gupta S, Snow RW, Donnelly C.A., Marsh K., Newbold C. (1999) Immunity to non-cerebral severe malaria is acquired after one or two infections. Nat Med 5: 340-343.
18. Lu S (2009) Heterologous prime-boost vaccination. Curr Opin Immunol 21: 346-351.
19. Nussenzweig RS, Vanderberg J, Most H., Orton C. (1967) Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei. Nature 216: 160-162.
20. Renia L, Marussig MS, Grillot D, Pied S., Corradin G, et al. (1991) In vitro activity of CD4+ and CD8+ T lymphocytes from mice immunized with a synthetic malaria peptide. Proc Natl Acad Sci U S A 88: 7963-7967.
21. Rieckmann KH, Beaudoin RL, Cassells J.S., Sell K.W. (1979) Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria. Bull World Health Organ 57 Suppl 1: 261-265.
22. Rodrigues M, Nussenzweig RS, Zavala F. (1993) The relative contribution of antibodies, CD4+ and CD8+ T cells to sporozoite-induced protection against malaria. Immunology 80: 1-5.
23. Snow RW, Guerra CA, Noor A.M., Myint HY, Hay S.I. (2005) The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434: 214-217.
24. Agnandji ST, Lell B, Fernandes J.F., Abossolo BP, Methogo BG, et al. (2012) A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. N Engl J Med 367: 2284-2295.
25. Bongfen SE, Ntsama PM, Offner S, Smith T., Felger I, et al. (2009) The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity. Vaccine 27: 328-335.
26. Vergara U, Ruiz A, Ferreira A., Nussenzweig RS, Nussenzweig V. (1985) Conserved group-specific epitopes of the circumsporozoite proteins revealed by antibodies to synthetic peptides. J Immunol 134: 3445-3448.
27. Kastenmuller K, Espinosa DA, Trager L, Stoyanov C., Salazar AM, et al. (2013) Full-length Plasmodium falciparum circumsporozoite protein administered with long-chain poly(I.C) or the Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant-stable emulsion elicits potent antibody and CD4+ T cell immunity and protection in mice. Infect Immun 81: 789-800.
28. Plassmeyer ML, Reiter K, Shimp R.L., Jr., Kotova S, Smith PD, et al. (2009) Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate. J Biol Chem 284: 26951-26963.
29. Ophorst OJ, Radosevic K, Havenga M.J., Pau MG, Holterman L, et al. (2006) Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice. Infect Immun 74: 313-320.
30. Anderson RC, Fox CB, Dutill T.S., Shaverdian N., Evers TL, et al. (2010) Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids Surf B Biointerfaces 75: 123-132.
31. Coler RN, Baldwin SL, Shaverdian N, Bertholet S., Reed SJ, et al. (2010) A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS One 5: e13677.
32. Gomes R, Teixeira C, Oliveira F., Lawyer PG, Elnaiem DE, et al. (2012) KSAC, a defined Leishmania antigen, plus adjuvant protects against the virulence of L. major transmitted by its natural vector Phlebotomus duboscqi. PLoS Negl Trop Dis 6: e1610.
33. Windish HP, Duthie MS, Misquith A, Ireton G., Lucas E, et al. (2011) Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate. Vaccine 29: 7842-7848.
34. Shiratsuchi T, Rai U, Krause A., Worgall S, Tsuji M. (2010) Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents preexisting immunity to adenovirus in mice. J Clin Invest 120: 3688-3701.
35. Hu SL, Abrams K, Barber G.N., Moran P., Zarling JM, et al. (1992) Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 255: 456-459.
36. Lu S (2006) Combination DNA plus protein HIV vaccines. Springer Semin Immunopathol 28: 255-265.
37. Arama C, Assefaw-Redda Y, Rodriguez A., Fernandez C, Corradin G, et al (2012) Heterologous prime-boost regimen adenovector 35-circumsporozoite protein vaccine/recombinant Bacillus Calmette-Guerin expressing the Plasmodium falciparum circumsporozoite induces enhanced long-term memory immunity in BALB/c mice. Vaccine 30: 4040-4045.
38. Li S, Rodrigues M, Rodriguez D., Rodriguez JR, Esteban M, et al. (1993) Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc Natl Acad Sci U S A 90: 5214-5218.
39. Reyes-Sandoval A., Harty JT, Todryk S.M. (2007) Viral vector vaccines make memory T cells against malaria. Immunology 121: 158-165.
40. Shott JP, McGrath SM, Pau M.G., Custers JH, Ophorst O, et al. (2008) Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumspor-ozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice. Vaccine 26: 2818-2823.
41. Yang TC, Millar JB, Grinshtein N, Bassett J., Finn J, et al. (2007) T-cell immunity generated by recombinant adenovirus vaccines. Expert Rev Vaccines 6: 347-356.
42. Rodrigues EG, Zavala F, Eichinger D., Wilson JM, Tsuji M. (1997) Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cellmediated protective immunity against malaria. J Immunol 158: 1268-1274.
43. Stewart VA, McGrath SM, Dubois P.M., Pau MG, Mettens P, et al. (2007) Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS, S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infect Immun 75: 2283-2290.
44. Creech CB, Dekker CL, Ho D, Phillips S., Mackey S, et al. (2013) Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults. Hum Vaccin Immunother 9: 2548-2557.
45. Keefer MC, Gilmour J, Hayes P., Gill D, Kopycinski J, et al (2012) A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One 7: e41936.
46. Ouedraogo A, Tiono AB, Kargougou D, Yaro J.B., Ouedraogo E., et al. (2013) A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age. PLoS One 8: e78679.
47. Dunachie SJ, Hill A.V. (2003) Prime-boost strategies for malaria vaccine development. J Exp Biol 206: 3771-3779.
48. Schofield L (1990) The circumsporozoite protein of Plasmodium: a mechanism of immune evasion by the malaria parasite? Bull World Health Organ 68 Suppl: 66-73.
49. Coppi A, Tewari R, Bishop J.R., Bennett BL, Lawrence R, et al. (2007) Heparan sulfate proteoglycans provide a signal to Plasmodium sporozoites to stop migrating and productively invade host cells. Cell Host Microbe 2: 316-327.
50. Alonso PL, Sacarlal J, Aponte J.J., Leach A., Macete E, et al. (2004) Efficacy of the RTS, S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364: 1411-1420.
51. Asante KP, Abdulla S, Agnandji S., Lyimo J, Vekemans J, et al (2011) Safety and efficacy of the RTS, S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Lancet Infect Dis 11: 741-749.
52. Ndungu FM, Mwacharo J, Kimani D., Kai O, Moris P, et al (2012) A statistical interaction between circumsporozoite protein-specific T cell and antibody responses and risk of clinical malaria episodes following vaccination with RTS, S/AS01E. PLoS One 7: e52870.
53. Fox CB, Baldwin SL, Vedvick T.S., Angov E., Reed S.G. (2012) Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines. Clin Vaccine Immunol 19: 1633-1640.
54. Behzad H, Huckriede AL, Haynes L, Gentleman B., Coyle K, et al. (2012) GLASE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults. J Infect Dis 205: 466-473.
55. Treanor JJ, Essink B, Hull S., Reed S, Izikson R, et al (2013) Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant. Vaccine 31: 5760-5765.
56. Radosevic K, Rodriguez A, Lemckert A.A., van der Meer M, Gillissen G, et al. (2010) The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert. Clin Vaccine Immunol 17: 1687-1694.
57. Baldwin SL, Ching LK, Pine S.O., Moutaftsi M., Lucas E, et al. (2013) Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cells. J Immunol 191: 2514-2525.
58. Retallack DM, Jin H, Chew L. (2012) Reliable protein production in a Pseudomonas fluorescens expression system. Protein Expr Purif 81: 157-165.
59. Haaland P, Samarov D, McVey E. (2011) calibFit: Statistical models and tools for assay calibration (R package version 2.1.0). Available at: http://cran.r-project.org/web/packages/calibFit/index.html (Accessed on 15 December 2012).
60. R Core Team (2012) R: A language and environment for statistical computing. Vienna, Austria. Available: http://www.r-project.org/. Accessed 11 March 2013.
61. Persson C, Oliveira GA, Sultan A.A., Bhanot P., Nussenzweig V, et al. (2002) Cutting edge: a new tool to evaluate human pre-erythrocytic malaria vaccines: rodent parasites bearing a hybrid Plasmodium falciparum circumsporozoite protein. J Immunol 169: 6681-6685.
62. Bruna-Romero O., Hafalla JC, Gonzalez-Aseguinolaza G, Sano G., Tsuji M, et al. (2001) Detection of malaria liver-stages in mice infected through the bite of a single Anopheles mosquito using a highly sensitive real-time PCR. Int J Parasitol 31: 1499-1502.